Page 9 - View Large News Today : Breaking News, Live Updates & Top Stories | Vimarsana

“Racism is a public health emergency of global concern.” Since we wrote these words in June, 2020, a monumental worldwide reckoning with racism, xenophobia, and discrimination in society—its roots, its consequences, and its redress—has gathered pace. Marches have taken place and statues have been toppled, activists galvanised and institutions investigated, reforms proposed and elections contested. Progress has been uneven, but interrogation of the power structures that prejudice and mistreat specific groups of people while privileging others has heightened an acknowledgment of racism a...

Before our interview, Ntobeko Ntusi, Chair and Head of the Department of Medicine at the University of Cape Town (UCT) and Groote Schuur Hospital, South Africa, had been doing a bedside tutorial with students. He highlighted the different way they had presented the Black and White patients. “I asked the students why it is important to clarify the HIV status of Black patients when you present them when it has no bearing on their clinical presentation. And you can see the dumbfounded faces because it's not something they do consciously, but these biases are so in-built, even at this young age�...

Revered cardiovascular epidemiologist. He was born in New York, NY, USA, on Jan 9, 1934 and died of pneumonia in Pittsburgh, PA, USA, on Oct 25, 2022 aged 88 years.

Involving patients in all stages of health data research is a noble aim; however, there are not too many examples of it being successfully put into practice—particularly not in real-time pandemic surveillance. In November, 2020, the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) team created a unique collaboration, inviting a Public Advisory Group (PAG) of 15 patient and public contributors to work alongside university and Public Health Scotland staff to provide vital perspectives of the public on all areas of their COVID-19 research.

The Alzheimer's disease community has become accustomed to false hope, disappointment, and controversy. With an estimated 55 million people worldwide affected by dementia, the need for an effective treatment is undeniable. But efforts to develop a drug that can modify the course of Alzheimer's disease, by using antibodies to clear amyloid-beta (Aβ) from the brain, have endured numerous setbacks over the past 20 years. Almost a decade ago, the first anti-Aβ antibodies tested in phase 3 trials, bapineuzumab and solanezumab, did not improve clinical outcomes in mild to moderate Alzheimer's dise...